Fraunhofer ITEM: News

 

News / 3.12.2024

Inhale+

Fraunhofer ITEMs spin-off project receives a boost of €1.3 million. The technology aims to revolutionize inhalation therapy for premature babies.

Press Release / Research News / 1.8.2024

Toxicological assessment of e-liquids

Project EVape helps improve consumer safety in the e-cigarette segment.

Press release / 3.7.2024

DNA, RNA and peptides as storage media

BIOSYNTH – “Modular high-throughput micro-platform for mass data storage of the future from synthetic biology”

 

Press release / 25.7.2024

First patient dosed

OM Pharma and Fraunhofer ITEM announce initiation of a phase Ia/Ib clinical trial evaluating safety and tolerability of OM-85-Intranasal (IN).

 

News / 16.10.2024

Revision of TRGS 529

Researchers at Fraunhofer ITEM are using biological tests to investigate the safety of trace element products for biogas plants.

Press release / 16.4.2024

Miniature Lab

New opportunity for cancer therapy: Miniature Lab provides insights into metastases development.

22.3.2024

EU project REGENERAR

3 million euros allocated for research into the development of innovative technologies for brain regeneration.

Press release / 1.2.2024

RNAi therapy for viral respiratory diseases

The iGUARD Project have made significant progress in developing a new antiviral therapy. 

Our research and development expertise

For more than four decades, we have been developing solutions for human health

 

Lung research

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

Medical and pharmaceutical engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.

 

Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.

 

RNA technologies

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.

 

Toxicology

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

 

Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Our services

 

Translational Biomedical Engineering

From idea to safe medical device:

 

 

Personalized Tumor Therapy

From molecular analysis to personalized therapy:

 

Meet Fraunhofer ITEM at fairs and congresses

Events

10.9.2025

Fraunhofer CIMD Symposium RNA-Based Therapeutics

RNA-research in the focus - at the Fraunhofer CIMD Symposium RNA-Based Therapeutics at Fraunhofer ITEM in Hannover on September 10 and 11, 2025. Read more here.
more info

19.6.2025

Models of Lung Disease 2025

June 19 and 20 - our conference "Models of Lung Disease" for experts in lung reserach. Please save the date for the 23rd Fraunhofer Seminar "Models of Lung Disease". Join us! We would be pleased to welcoming you there.
more info

16.5.2025

RIS and ATS 2025

This year’s ATS International Conference will be held in San Francisco (USA) from May 16 to 21, 2025. On the first two days, the Respiratory Innovation Summit (RIS) takes place as a pre-conference to the ATS. Pre-Conference RIS: May 16-17 International Conference: May 18-21
more info

13.5.2025

Fraunhofer Symposium on Nanotechnology

At the 5th Symposium on Nanotechnology of the Fraunhofer Nanotechnology Network, with the support of the Federal Institute for Risk Assessment (BfR), will once again address the opportunities and risks associated with this rapidly evolving field. The two-day event at the Fraunhofer Institute for Silicate Research ISC in Würzburg will address a range of topics related to the application of nanotechnology in various sectors, including digitalization, 2D/3D printing, carbon-based materials and battery materials. Please note that the event will be conducted in English in presence. Registration is open until April 22, 2025. The number of places is limited.
more info

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on lung research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of around 450 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.

 

More information about Fraunhofer ITEM